Attack Rate Reductions After Berotralstat Initiation Among Patients With Hereditary Angioedema

Davis-Lorton M, Tachdjian R, Yee T, et al

This retrospective real-world pre–post study evaluated the impact of berotralstat on hereditary angioedema attack rates in patients with normal C1-inhibitor, stratified by prior long-term prophylaxis use. Berotralstat was associated with significant reductions in monthly attack rates in both long-term prophylaxis-naïve and long-term prophylaxis-experienced patients over 12 to 18 months. These findings support its effectiveness as an oral prophylactic option in patients with hereditary angioedema and normal C1-inhibitor regardless of prior treatment history.